Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
27 09 2023
27 09 2023
Historique:
received:
19
04
2023
accepted:
23
08
2023
revised:
08
08
2023
medline:
28
9
2023
pubmed:
27
9
2023
entrez:
26
9
2023
Statut:
epublish
Résumé
Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active multiple myeloma (MM). The aim of this study was to report clinical characteristics and outcomes of patients with SMM stratified based on their risk of progression to MM using the Mayo 20/2/20 criteria. Data were leveraged from the Czech Myeloma Group Registry of Monoclonal Gammopathies (RMG). Key outcomes included progression-free survival from SMM diagnosis to active MM diagnosis or death (PFS), progression-free survival from SMM diagnosis to progression on first line (1 L) MM treatment or death (PFS2), and overall survival (OS). Of 498 patients, 174 (34.9%) were classified as high risk and 324 (65.1%) as non-high risk. Median follow-up was approximately 65 months. During follow-up, more patients in the high-risk vs non-high-risk group received 1 L MM treatment (76.4% vs 46.6%, p < 0.001). PFS, PFS2, and OS were significantly shorter in high-risk vs non-high-risk patients (13.2 vs 56.6 months, p < 0.001; 49.9 vs 84.9 months, p < 0.001; 93.2 vs 131.1 months, p = 0.012, respectively). The results of this study add to the growing body of evidence that patients with high-risk vs non-high-risk SMM have significantly worse outcomes, including OS.
Identifiants
pubmed: 37752128
doi: 10.1038/s41408-023-00906-7
pii: 10.1038/s41408-023-00906-7
pmc: PMC10522616
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
153Informations de copyright
© 2023. Springer Nature Limited.
Références
Rajkumar SV, Landgren O, Mateos MV. Smoldering multiple myeloma. Blood. 2015;125:3069–75. https://doi.org/10.1182/blood-2014-09-568899 .
doi: 10.1182/blood-2014-09-568899
pubmed: 25838344
pmcid: 4432003
UAMS Health. Smoldering myeloma. 2022. https://uamshealth.com/condition/smoldering-myeloma/ .
Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48. https://doi.org/10.1016/S1470-2045(14)70442-5 .
doi: 10.1016/S1470-2045(14)70442-5
pubmed: 25439696
Ravindran A, Bartley AC, Holton SJ, Gonsalves WI, Kapoor P, Siddiqui MA, et al. Prevalence, incidence and survival of smoldering multiple myeloma in the United States. Blood Cancer J. 2016;6:e486. https://doi.org/10.1038/bcj.2016.100 .
doi: 10.1038/bcj.2016.100
pubmed: 27768092
pmcid: 5098258
Kristinsson SY, Holmberg E, Blimark C. Treatment for high-risk smoldering myeloma. N Engl J Med. 2013;369:1762–3. https://doi.org/10.1056/NEJMc1310911 .
doi: 10.1056/NEJMc1310911
pubmed: 24171527
Thorsteinsdottir S, Gislason G, Aspelund A, Rögnvaldsson S, Oskarsson J, Petursdottir I, et al. Prevalence of smoldering multiple myeloma: results from the Iceland screens, treats, or prevents multiple myeloma (iStopMM) study. Blood. 2021;138:151.
doi: 10.1182/blood-2021-148617
Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007;356:2582–90. https://doi.org/10.1056/NEJMoa070389 .
doi: 10.1056/NEJMoa070389
pubmed: 17582068
Vaxman I, Gertz MA. How I approach smoldering multiple myeloma. Blood. 2022;140:828–38. https://doi.org/10.1182/blood.2021011670 .
doi: 10.1182/blood.2021011670
pubmed: 35576526
pmcid: 9412010
Visram A, Cook J, Warsame R. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies. Hematology Am Soc Hematol Educ Program. 2021;2021:673–81. https://doi.org/10.1182/hematology.2021000304 .
doi: 10.1182/hematology.2021000304
pubmed: 34889380
pmcid: 8791169
Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8:59. https://doi.org/10.1038/s41408-018-0077-4 .
doi: 10.1038/s41408-018-0077-4
pubmed: 29895887
pmcid: 5997745
Mateos MV, Kumar S, Dimopoulos MA, Gonzalez-Calle V, Kastritis E, Hajek R, et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020;10:102. https://doi.org/10.1038/s41408-020-00366-3 .
doi: 10.1038/s41408-020-00366-3
pubmed: 33067414
pmcid: 7567803
Hájek R, Sandecka V, Špička I, Raab M, Goldschmidt H, Beck S, et al. Identification of patients with smouldering multiple myeloma at ultra-high risk of progression using serum parameters: the Czech Myeloma Group model. Br J Haematol. 2020;190:189–97. https://doi.org/10.1111/bjh.16572 .
doi: 10.1111/bjh.16572
pubmed: 32163180
Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Hemasphere. 2021;5:e528. https://doi.org/10.1097/HS9.0000000000000528 .
doi: 10.1097/HS9.0000000000000528
pubmed: 33554050
pmcid: 7861652
National Comprehensive Cancer Network. NCCN Guidelines Version 5.2022. Multiple Myeloma. 2022. https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf .
Brozova L, Schwarz D, Snabl I, Kalina J, Pavlickova B, Komenda M, et al. Czech Registry of Monoclonal Gammopathies - technical solution, data collection and visualisation. Klin Onkol. 2017;30:43–50. https://doi.org/10.14735/amko20172S43 .
doi: 10.14735/amko20172S43
pubmed: 28903570
Hájek R, Jarkovsky J, Maisnar V, Pour L, Špička I, Minařík J, et al. Real-world outcomes of multiple myeloma: retrospective analysis of the Czech Registry of Monoclonal Gammopathies. Clin Lymphoma Myeloma Leuk. 2018;18:e219–40. https://doi.org/10.1016/j.clml.2018.04.003 .
doi: 10.1016/j.clml.2018.04.003
pubmed: 29793653
Maluskova D, Svobodová I, Kucerova M, Brozova L, Muzik J, Jarkovský J, et al. Epidemiology of multiple myeloma in the Czech Republic. Klin Onkol. 2017;30:35–42. https://doi.org/10.14735/amko20172S35 .
doi: 10.14735/amko20172S35
pubmed: 28903569
Lonial S, Jacobus S, Fonseca R, Weiss M, Kumar S, Orlowski RZ, et al. Randomized trial of lenalidomide versus observation in smoldering multiple myeloma. J Clin Oncol. 2020;38:1126–37. https://doi.org/10.1200/JCO.19.01740 .
doi: 10.1200/JCO.19.01740
pubmed: 31652094
Tessier C, Allard T, Boudreault JS, Kaedbey R, Ethier V, Fortin F, et al. Testing Mayo Clinic’s New 20/20/20 risk model in another cohort of smoldering myeloma patients: a retrospective study. Curr Oncol. 2021;28:2029–39. https://doi.org/10.3390/curroncol28030188 .
doi: 10.3390/curroncol28030188
pubmed: 34073289
pmcid: 8161809
Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, et al. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016;17:1127–36. https://doi.org/10.1016/S1470-2045(16)30124-3 .
doi: 10.1016/S1470-2045(16)30124-3
pubmed: 27402145
Mateos MV, Hernández MT, Salvador C, Rubia J, de Arriba F, López-Corral L, et al. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: a randomized, open-label study. Eur J Cancer. 2022;174:243–50. https://doi.org/10.1016/j.ejca.2022.07.030 .
doi: 10.1016/j.ejca.2022.07.030
pubmed: 36067617
Dimopoulos M, Voorhees P, Goldschmidt H, Baker R, Shi Y, Rousseau E, et al. Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): randomized, open-label, phase 3 AQUILA study. J Clin Oncol. 2022;40:TPS8075.
doi: 10.1200/JCO.2022.40.16_suppl.TPS8075
Ghobrial I, Rodríguez-Otero P, Koh Y, Martínez-López J, Parmar G, Prince M, et al. ITHACA, a randomized multicenter phase 3 study of Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma: safety run-in preliminary results. Clin Lymphoma Myeloma Leuk. 2021;21:S109–10.
doi: 10.1016/S2152-2650(21)02264-3
Baertsch MA, Lutz R, Raab MS, Weinhold N, Goldschmidt H. Meeting report of the 7th Heidelberg Myeloma Workshop: today and tomorrow. J Cancer Res Clin Oncol. 2019;145:2445–55. https://doi.org/10.1007/s00432-019-02998-w .
doi: 10.1007/s00432-019-02998-w
pubmed: 31407112